The Recall Desk

Hazard

Cross Contamination recalls

439 recalls in our database tag this hazard, drawn from FDA, USDA FSIS, CPSC, and NHTSA source notices.

What the numbers show

Total
439
Critical
6
Severe
158
Most recent
2026-10-07

Of the 439 cross contamination recalls we have scored against our rubric, 6 (1%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 158 (36%) are Severe.

About this hazard tag

Hazard tags are short, machine-readable labels we attach to every recall to make cross-cutting queries possible — “all cross contamination recalls regardless of agency”, “all listeria recalls in California”, “all airbag recalls in 2025”. The tags are extracted from each recall’s source text during the LLM rewrite step and validated against a fixed schema.

A recall can carry multiple tags — a Listeria recall might also be tagged ready-to-eat and undeclared-allergen. Use the full-text search if you want to combine hazard tags with brand or category filters.

276–300 of 439

  • SevereFDA (Drugs)·D-762-2015·2015-04-29

    Attix Pharmaceuticals Recalls Lidocaine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Lidocaine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Lidocaine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-567-2015·2015-04-29

    Attix Pharmaceuticals Recalls Cefazolin Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Cefazolin Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Cefazolin Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-944-2015·2015-04-29

    Attix Pharmaceuticals Recalls Trifluridine API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Trifluridine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Trifluridine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-571-2015·2015-04-29

    Attix Pharmaceuticals Recalls Cephalexin Due to Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling cephalexin active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Cephalexin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-636-2015·2015-04-29

    Attix Pharmaceuticals Recalls Docetaxel Anhydrous Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Docetaxel Anhydrous active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Docetaxel Anhydrous active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-804-2015·2015-04-29

    Mitotane API Recalled for Potential Penicillin Cross-Contamination

    Attix Pharmaceuticals is recalling Mitotane active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Mitotane active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-710-2015·2015-04-29

    Attix Pharmaceuticals Recalls Hyaluronic Acid Sodium Salt Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Hyaluronic Acid Sodium Salt (Pharma Grade) active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Hyaluronic Acid Sodium Salt (Pharma Grade) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-907-2015·2015-04-29

    Attix Pharmaceuticals Recalls Sulfathiazole Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Sulfathiazole active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging. The product was distributed to compounding pharmacies and research organizations.

    Product
    Sulfathiazole active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-649-2015·2015-04-29

    Attix Pharmaceuticals Recalls Enzalutamide API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling enzalutamide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Enzalutamide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-854-2015·2015-04-29

    Attix Pharmaceuticals Recalls Prazosin HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Prazosin HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Prazosin HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-933-2015·2015-04-29

    Tobramycin Sulfate Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Tobramycin Sulfate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Tobramycin Sulfate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-629-2015·2015-04-29

    Attix Pharmaceuticals Recalls Diclofenac Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Diclofenac Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Diclofenac Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-559-2015·2015-04-29

    Attix Pharmaceuticals Recalls Capecitabine Due to Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling capecitabine active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Capecitabine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-810-2015·2015-04-29

    Attix Pharmaceuticals Recalls Mycophenolate Mofetil Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Mycophenolate Mofetil active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Mycophenolate Mofetil active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-568-2015·2015-04-29

    Attix Pharmaceuticals Recalls Cefixime API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Cefixime active pharmaceutical ingredient (API) due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Cefixime active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-943-2015·2015-04-29

    Attix Pharmaceuticals Recalls Trichlormethiazide Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Trichlormethiazide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Trichlormethiazide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-821-2015·2015-04-29

    Attix Pharmaceuticals Recalls Ofloxacin Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Ofloxacin active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Ofloxacin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-877-2015·2015-04-29

    Attix Pharmaceuticals Recalls Reserpine Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling reserpine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Reserpine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-911-2015·2015-04-29

    Attix Pharmaceuticals Recalls Tadalafil API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Tadalafil active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Tadalafil active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-656-2015·2015-04-29

    Attix Pharmaceuticals Recalls Estriol Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Estriol active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging. The product was distributed to compounding pharmacies and research organizations.

    Product
    Estriol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-842-2015·2015-04-29

    Attix Pharmaceuticals Recalls Pimecrolimus Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Pimecrolimus active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Pimecrolimus active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-888-2015·2015-04-29

    Secnidazole API Recalled for Potential Penicillin Cross-Contamination

    Attix Pharmaceuticals is recalling Secnidazole active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Secnidazole active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-682-2015·2015-04-29

    Fluorescein Sodium Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Fluorescein Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Fluorescein Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-949-2015·2015-04-29

    Vancomycin HCl Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Vancomycin HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Vancomycin HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-590-2015·2015-04-29

    Attix Pharmaceuticals Recalls Cisplatin Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling cisplatin active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Cisplatin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide